A meta-analysis by the researchers at the Umea University, Sweden shows no reduction in death and cardiovascular disease risks with blood pressure lowering treatments among healthy people with systolic blood pressure below 140 mm Hg.
Systolic Blood Pressure Intervention Trial (SPRINT), a previous study done in 2015 has found a reduction in mortality and cardiovascular disease with a systolic blood pressure less than 120 mm Hg. But current study finding was opposite to SPRINT study finding and supports current guidelines.
Researchers have conducted a meta-analysis, which combines 74 randomized clinical trials conducted on more than 306,273 patients. The average age of the participants was 63.6 years and 39.9 percent of them were women participants. The analytical study found that the benefits of the reduction in systolic blood pressure of less than 140 mm Hg depends on its reading when an individual was healthy. There are no effects on mortality or cardiovascular events if the systolic blood pressure was below 140 mm Hg prior to first-ever cardiovascular events.
Lead author of the study was Dr. Mattias Brannstrom, MD, PhD, a researcher, the Department of Public Health and Clinical Medicine, Umea University, Sweden. The study findings were published October 1, 2017, in the JAMA Internal Medicine. Title of the article was "Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis."
A trodusquemine drug was effective in reducing weight (by stopping PTP1B enzyme) and inflammation, to suppress appetite, in improving insulin resistance associated with obesity and for the treatment of breast cancer. But a current study done by researchers at the University of Aberdeen, Scotland, shows a reduction in arterial fat and possible reversal of atherosclerosis (a risk factor for heart and cardiovascular CVD diseases) with a trodusquemine drug.
Preclinical studies with mice model show a trodusquemine drug has the ability to dissipate plaque and fat in the arteries. In some cases, just one dose is sufficient for the reversal of atherosclerosis. Study results show a decrease in the measured plaque formation, the complete reversal of atherosclerosis effects and prevention of risks associated with occlusion and thrombosis events.
The trodusquemine drug dosage of either once a week for five weeks or just once at the end of the study has resulted in a marked reduction in the atherosclerotic plaque area along with lower cholesterol and triglycerides.
Authors of the study were Professor Mirela Delibegovic and Dr. Dawn Thompson from the University of Aberdeen's Institute of Medical Sciences, Aberdeen, Scotland. The study findings were published 29 September 2017, in the Clinical Science. Title of the article was "Pharmacological inhibition of protein tyrosine phosphatase 1B protects against atherosclerotic plaque formation in the LDLR-/- mouse model of atherosclerosis."
Occlusion : A clot blocking a blood vessel is known as vascular occlusion. The blockage may be partial or complete and leads to heart attack. This can be diagnosed with an ultrasound technique known as Doppler sonography.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.